More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreatedLTC residents are often ...

The novel PDE10A inhibitor CPL'36 offers a new mechanism of action and is both safe and effective for acute exacerbations of schizophrenia, new research suggests.